SEC Company Response from Cocrystal Pharma, Inc. (COCP) (CIK 0001412486) (COCP) — May 11, 2020
Cocrystal Pharma, Inc. (COCP) (CIK 0001412486)
Date: May 11, 2020 · CIK: 0001412486 · Accession: 0001493152-20-008291
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-237738
Referenced dates: April 27, 2020
Letter
VIA EDGAR Division of Corporation Finance Attention: Mr. Tim Buchmiller Re: Cocrystal Pharma, Inc. Registration Statement on Form S-3 Filed April 17, 2020 File No. 333-237738
Dear Mr. Buchmiller:
Confirming our telephone conversation this afternoon with respect to the “futures” effect of Comment No. 4 in the Staff’s comment letter dated April 27, 2020, this letter confirms on behalf of our client, Cocrystal Pharma, Inc. (“Cocrystal”) that in future filings with the Commission on Form 10-K as well as any prospectus supplements or new registration statements on Form S-3 or S-1, Cocrystal will disclose the effect of the charter amendment on exclusive jurisdiction in the same manner as it did in Amendment No. 1 to Form S-3 filed on May 4, 2020.
If you have any questions, please contact the undersigned at (561) 644-2222 or at mharris@nasonyeager.com.
Sincerely
yours,
NASON,
YEAGER, GERSON,
Show Raw Text
CORRESP
1
filename1.htm
MICHAEL
D. HARRIS
DIRECT
DIAL:
(561)
471-3507
ALSO
ADMITTED IN NEW YORK
E-MAIL
ADDRESS: mharris@nasonyeager.com
May
11, 2020
VIA
EDGAR
Division
of Corporation Finance
U.S.
Securities and Exchange Commission
Washington,
DC 20549
Attention:
Mr. Tim Buchmiller
Re:
Cocrystal
Pharma, Inc.
Registration
Statement on Form S-3
Filed
April 17, 2020
File
No. 333-237738
Dear
Mr. Buchmiller:
Confirming
our telephone conversation this afternoon with respect to the “futures” effect of Comment No. 4 in the Staff’s
comment letter dated April 27, 2020, this letter confirms on behalf of our client, Cocrystal Pharma, Inc. (“Cocrystal”)
that in future filings with the Commission on Form 10-K as well as any prospectus supplements or new registration statements on
Form S-3 or S-1, Cocrystal will disclose the effect of the charter amendment on exclusive jurisdiction in the same manner as it
did in Amendment No. 1 to Form S-3 filed on May 4, 2020.
If
you have any questions, please contact the undersigned at (561) 644-2222 or at mharris@nasonyeager.com.
Sincerely
yours,
NASON,
YEAGER, GERSON,
HARRIS & FUMERO, P.A.
/s/
Michael D. Harris
cc:
Dr.
Gary Wilcox (via email)
Mr.
James Martin
3001
PGA BOULEVARD, SUITE 305
PALM
BEACH GARDENS, FLORIDA 33410
TELEPHONE
(561) 686-3307